Targa Therapeutics Corp. – Product Pipeline Review – H2 2011

Document Sample
Targa Therapeutics Corp. – Product Pipeline Review – H2 2011 Powered By Docstoc
					Targa Therapeutics Corp. – Product Pipeline Review




 Targa Therapeutics Corp. – Product Pipeline Review –
                      H2 2011


                                                                                          Reference Code: GMDHC02090CDB
                                                                                                 Publication Date: DEC 2011




Targa Therapeutics Corp. – Product Pipeline Review – H2 2011                              GMDHC02090CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Targa Therapeutics Corp. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 4
Targa Therapeutics Corp. Snapshot .................................................................................................................................................. 5
    Targa Therapeutics Corp. Overview .............................................................................................................................................. 5
    Key Information ............................................................................................................................................................................. 5
    Key Facts....................................................................................................................................................................................... 5
Targa Therapeutics Corp. – Research and Development Overview .................................................................................................. 6
    Key Therapeutic Areas .................................................................................................................................................................. 6
Targa Therapeutics Corp. – Pipeline Review ..................................................................................................................................... 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
Targa Therapeutics Corp. – Pipeline Products Glance .................................................................................................................... 11
    Targa Therapeutics Corp. Clinical Stage Pipeline Products ........................................................................................................ 11
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 11
    Targa Therapeutics Corp. – Early Stage Pipeline Products ........................................................................................................ 12
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 12
Targa Therapeutics Corp. – Drug Profiles ........................................................................................................................................ 13
    BreMel/TNF-a .............................................................................................................................................................................. 13
        Product Description................................................................................................................................................................. 13
        Mechanism of Action ............................................................................................................................................................... 13
        R&D Progress ......................................................................................................................................................................... 13
    Granzyme B/VEGF ...................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    HuM195/rGel ............................................................................................................................................................................... 15
        Product Description................................................................................................................................................................. 15
        Mechanism of Action ............................................................................................................................................................... 15
        R&D Progress ......................................................................................................................................................................... 15
    scFvMel/rGel ............................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    VEGF/rGel ................................................................................................................................................................................... 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
Targa Therapeutics Corp. – Pipeline Analysis.................................................................................................................................. 19
    Targa Therapeutics Corp. – Pipeline Products by Therapeutic Class ......................................................................................... 19
    Targa Therapeutics Corp. - Pipeline Products By Target ............................................................................................................ 20
    Targa Therapeutics Corp. – Pipeline Products by Route of Administration ................................................................................. 22



Targa Therapeutics Corp. – Product Pipeline Review – H2 2011                                                                           GMDHC02090CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                      Page(2)
Targa Therapeutics Corp. – Product Pipeline Review




    Targa Therapeutics Corp. – Pipeline Products by Molecule Type ............................................................................................... 23
Targa Therapeutics Corp. – Locations And Subsidiaries.................................................................................................................. 24
    Head Office.................................................................................................................................................................................. 24
Financial Deals Landscape .............................................................................................................................................................. 25
    Targa Therapeutics Corp., Deals Summary .........................................................................................................
				
DOCUMENT INFO
Description: Targa Therapeutics Corp. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Targa Therapeutics Corp. - Product Pipeline Review - H2 2011” provides data on the Targa Therapeutics Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Targa Therapeutics Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Targa Therapeutics Corp. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Targa Therapeutics Corp. - Brief Targa Therapeutics Corp. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Targa Therapeutics Corp. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Targa Therapeutics Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Targa Therapeutics Corp.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Targa Therapeutics Corp.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Targa Therapeutics Corp. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Targa Therapeutics Corp.’s R&D portfolio and develop key strat
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries